Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis

FASEB Journal

Volumn 15, Issue 6, 2001, Pages 916-926

  Lee, Frank J S ^a,c   Liu, Fang ^c   Pristupa, Zdenek B ^c   Niznik, Hyman B ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Cell death; Coimmunoprecipitation; DA uptake; GST fusion proteins; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; DOPAMINE TRANSPORTER;

APOPTOSIS; ARTICLE; COMPLEX FORMATION; DEGENERATIVE DISEASE; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; GENETIC TRANSFECTION; HUMAN; MUTATION; NERVE ENDING; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ALPHA-SYNUCLEIN; APOPTOSIS; CARRIER PROTEINS; CELLS, CULTURED; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEURONS; SYNUCLEINS; TRANSFECTION;

EID: 0035066885     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.00-0334com     Document Type: Article

References (85)

1. Mutation in the α-synuclein gene identified in families with Parkinson's disease
2. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease
3. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease
4. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
5. Etiology and pathogenesis of Parkinson's disease
6. Dopaminergic loss and inclusion body formation in alpha-synuclein mice, implications for neurodegenerative disorders
7. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease
8. α-Synuclein in Lewy bodies
9. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
10. Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes
11. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein
12. Synucleins in synaptic plasticity and neurodegenerative disorders
13. The synuclein family
14. Synoretin - A new protein belonging to the synuclein family
15. Identification of two distinct synucleins from human brain
16. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes
17. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded
18. Regulation of phospholipase D2, selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins
19. Degradation of α-synuclein by proteasome
20. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins
21. Constitutive phosphorylation of the Parkinson's disease associated α-synuclein
22. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system
23. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
24. Pharmacology and regulation of the neuronal dopamine transporter
25. Profound neuronal plasticity in response to inactivation of the dopamine transporter
26. Metals and free radicals in neurodegeneration
27. Oxidative stress and neuroprotection in Parkinson's disease, implications from studies on dopamine-induced apoptosis
28. Oxidative mechanisms in nigral cell death in Parkinson's disease
29. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, uptake of the metabolite N-methyl 4-phenylpyridine by dopamine neurons explains selective toxicity
30. The dopamine transporter carboxyl-terminal tail. Truncation/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain
31. Direct protein-protein coupling enables cross-talk between Dopamine D5 and γ-aminobutyric acid A receptors
32. Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy Body Disease
33. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions
34. Binding of Aβ to α- and β-synucleins, identification of segments in α-synuclein/NAC precursor that bind Aβ and NAC
35. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system
36. NACP, the precursor protein of the non-amyloid β/A4 protein (A beta) component of Alzheimer disease amyloid, binds Aβ and stimulates Aβ aggregation
37. Characterization of the precursor protein of the non-Aβ component of senile plaques (NACP) in the human central nervous system
38. α-Synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356
39. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity
40. α-Synuclein expression in substantia nigra and cortex in Parkinson's disease
41. Immunocytochemical localization of the dopamine transporter in human brain
42. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons
43. Functional hyperdopaminergia in dopamine transporter knockout mice
44. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter
45. Membrane trafficking regulates the activity of the human dopamine transporter
46. Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters
47. Immunogold localization of the dopamine transporter, an ultrastructural study of the rat ventral tegmental area
48. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra
49. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons
50. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway
51. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: Is NAC a common trigger or target in neurodegenerative disease?
52. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease
53. Toxicity of non-Aβ component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of β-sheet structure and fibrils
54. Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments
55. Alpha-synuclein and Parkinson's disease, selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo
56. Protein kinase C activators decrease dopamine uptake into striatal synaptosomes
57. Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes
58. Regulation of the functional activity of the human dopamine transporter by protein kinase C
59. Protein kinase C regulates the interaction between a GABA transporter and syntaxin 1A
60. The glut 1 glucose transporter interacts with calnexin and calreticulin
61. Protein interactions with the glucose transporter binding protein GLUT1CBP that provide a link between GLUT1 and the cytoskeleton
62. Cocaine upregulates the dopamine transporter in fetal rhesus monkey brain
63. Striatal dopaminergic abnormalities in human cocaine users
64. Dopamine transporter density in patients with attention deficit hyperactivity disorder
65. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
66. α-Synuclein in neurodegenerative disorders, murderer or accomplice?
67. Aggregation of neurofilament and α-synuclein proteins in Lewy bodies, implications for the pathogenesis of Parkinson disease and Lewy body dementia
68. Aberrant protein deposition and neurological disease
69. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture
70. Oxidative stress and neuroprotection in Parkinson's disease, implications from studies on dopamine-induced apoptosis
71. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria, implications for Parkinson's disease
72. Mitochondria and cell death
73. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway
74. Intrastriatal dopamine injection induces apoptosis through oxidation-involved activation of transcription factors AP-1 and NF-kappaB in rats
75. (-) -Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide
76. + in vivo
77. Bcl-2 inhibition of neural death, decreased generation of reactive oxygen species
78. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons
79. Synuclein expression is decreased in rat substantia nigra following induction of apoptosis by intrastriatal 6-hydroxydopamine
80. Cell death mechanisms in Parkinson's disease
81. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro
82. Biochemical aspects of Parkinson's disease
83. Role of mitochondria in Parkinson disease
84. Modification of dopamine transporter function, effect of reactive oxygen species and dopamine
85. Dopamine transporters and neuronal injury